News & Updates

ACEIs/ARBs prevent hepatocellular carcinoma, cirrhotic complications in NAFLD

08 Sep 2021 by

Treatment with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) results in a reduced risk of hepatocellular carcinoma (HCC) and cirrhotic complications in patients with nonalcoholic fatty liver disease (NAFLD), particularly among those with chronic kidney disease (CKD), according to a study presented at the virtual Asian Pacific Digestive Disease Week (APDW) 2021.

ACEIs/ARBs prevent hepatocellular carcinoma, cirrhotic complications in NAFLD

08 Sep 2021

Rasburicase use for tumour lysis syndrome management needs improvement

08 Sep 2021

Use of rasburicase for the management of patients with tumour lysis syndrome in inpatient and outpatient settings may still be improved, suggests a study.

Rasburicase use for tumour lysis syndrome management needs improvement

08 Sep 2021

Oral n-acetyl cysteine may prevent post-ERCP acute pancreatitis

08 Sep 2021 by

Use of the oral antioxidant and anti-inflammatory n-acetyl cysteine (NAC) – be it alone or in combination with rectal indomethacin – may prevent the occurrence of post-ERCP* acute pancreatitis (PEAP), according to findings from a study presented at APDW 2021.

Oral n-acetyl cysteine may prevent post-ERCP acute pancreatitis

08 Sep 2021

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup

08 Sep 2021 by

Second-line treatment with tislelizumab improves overall survival (OS) in patients from Europe/North America (EU/NA) with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy, according to subgroup analysis of the RATIONALE 302* study presented at ESMO GI 2021.

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup

08 Sep 2021

Edoxaban matches VKA post-TAVI, at a cost: ENVISAGE-TAVI AF

07 Sep 2021 by

The NOAC* edoxaban was noninferior to VKA** for the primary composite outcome of net adverse clinical events (NACE) after a successful TAVI*** in patients with atrial fibrillation (AF), but this comes at the cost of higher major bleeding rates, according to the ENVISAGE-TAVI AF# trial — thus leaving the question on the optimal antithrombotic strategies in AF after TAVI unanswered.

Edoxaban matches VKA post-TAVI, at a cost: ENVISAGE-TAVI AF

07 Sep 2021

Pharmacists improve care of patients in ambulatory oncology clinic

07 Sep 2021

Pharmacy services being offered in an ambulatory oncology clinic are deemed important and highly satisfactory by patients, according to a recent study.

Pharmacists improve care of patients in ambulatory oncology clinic

07 Sep 2021

Nab-paclitaxel plus CRT on par with standard treatment in pancreatic cancer

07 Sep 2021 by

Concurrent chemoradiotherapy (CRT) with nab-paclitaxel for the treatment of borderline resectable or unresectable pancreatic cancer is well tolerated and contributes to fewer incidence of local failure and higher conversion to resectability, both of which are statistically nonsignificant, a study has shown.

Nab-paclitaxel plus CRT on par with standard treatment in pancreatic cancer

07 Sep 2021

Statins may prevent pancreatic cancer in Asians

07 Sep 2021

In a Japanese population, exposure to statins appears to confer a protective effect on the risk of developing pancreatic cancer, as reported in a study.

Statins may prevent pancreatic cancer in Asians

07 Sep 2021

Mirabegron effective for paediatric NDO patients

06 Sep 2021 by

The β3-adrenoreceptor agonist mirabegron – a proven effective treatment for overactive bladder and neurogenic detrusor overactivity (NDO) in adults – was equally as effective in children and adolescents with NDO, a phase III study suggests.

Mirabegron effective for paediatric NDO patients

06 Sep 2021

Drug therapy drives lipid changes in inflammatory bowel disease

06 Sep 2021

During inflammatory bowel disease (IBD) treatment, there appears to be a substantial elevation in total cholesterol levels that occurs with exposure to corticosteroids and tofacitinib but not with antitumour necrosis factor alpha (anti-TNFα) agents, according to the results of a meta-analysis.

Drug therapy drives lipid changes in inflammatory bowel disease

06 Sep 2021

News & Updates

Filter by Specialty:

Specialty:

ACEIs/ARBs prevent hepatocellular carcinoma, cirrhotic complications in NAFLD

ACEIs/ARBs prevent hepatocellular carcinoma, cirrhotic complications in NAFLD

Rasburicase use for tumour lysis syndrome management needs improvement

Rasburicase use for tumour lysis syndrome management needs improvement

Oral n-acetyl cysteine may prevent post-ERCP acute pancreatitis

Oral n-acetyl cysteine may prevent post-ERCP acute pancreatitis

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup

Second-line tislelizumab improves OS in advanced/metastatic ESCC in European/North American subgroup

Edoxaban matches VKA post-TAVI, at a cost: ENVISAGE-TAVI AF

Edoxaban matches VKA post-TAVI, at a cost: ENVISAGE-TAVI AF

Pharmacists improve care of patients in ambulatory oncology clinic

Pharmacists improve care of patients in ambulatory oncology clinic

Nab-paclitaxel plus CRT on par with standard treatment in pancreatic cancer

Nab-paclitaxel plus CRT on par with standard treatment in pancreatic cancer

Statins may prevent pancreatic cancer in Asians

Statins may prevent pancreatic cancer in Asians

Mirabegron effective for paediatric NDO patients

Mirabegron effective for paediatric NDO patients

Drug therapy drives lipid changes in inflammatory bowel disease

Drug therapy drives lipid changes in inflammatory bowel disease